Adverse Effects Associated with Cancer Immunotherapies

Hareesh Singam, MD
Thursday, April 22, 2021
Category: Immunocompromised Host, Infectious in Oncology, Transplant Infectious Diseases

Dr. Hareesh Singam, infectious diseases senior fellow at the University of South Florida College of Medicine, discusses some of the side effects associated with newer cancer therapies in this informative podcast. Dr. Singam broadly divides his remarks into two categories: Syndromes related to Immune Checkpoint Inhibitors, and Syndromes related to CAR-T Cell Therapy. He begins by briefly introducing the Immune Checkpoint Inhibitors (ICIs) and their mechanisms of action. He then discusses mechanisms of ICI toxicity and their clinical features. Dr. Singam goes on to discuss the associated infectious risks and how they are managed. Next, Dr Singham moves on to CAR-T Cell therapy, including its mechanisms of action, what occurs with cytokine release syndrome (CRS), and describes CAR-T Related Encephalopathy (CRES), CAR-T related hematophagic lyphohistiocytosis/macrophage activation syndrome (HLH/MAS), and the factors behind infectious risk after CAR-T therapy. Lastly, Dr. Singam discusses the use of Tocilizumab in CAR-T therapy.

Stay in touch! Download our app in the iTunes store or the Google Marketplace.